Cargando…
Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
The significance of Akkermansia bacteria presence in gut micobiome, mainly Akkermansia mucinifila, is currently being investigated in the context of supporting therapy and marker for response to immunotherapy in cancer patients. It is indicated that patients with non-small cell lung cancer (NSCLC) t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259768/ https://www.ncbi.nlm.nih.gov/pubmed/35792976 http://dx.doi.org/10.1186/s13568-022-01428-4 |
_version_ | 1784741856782843904 |
---|---|
author | Grenda, Anna Iwan, Ewelina Chmielewska, Izabela Krawczyk, Paweł Giza, Aleksandra Bomba, Arkadiusz Frąk, Małgorzata Rolska, Anna Szczyrek, Michał Kieszko, Robert Kucharczyk, Tomasz Jarosz, Bożena Wasyl, Dariusz Milanowski, Janusz |
author_facet | Grenda, Anna Iwan, Ewelina Chmielewska, Izabela Krawczyk, Paweł Giza, Aleksandra Bomba, Arkadiusz Frąk, Małgorzata Rolska, Anna Szczyrek, Michał Kieszko, Robert Kucharczyk, Tomasz Jarosz, Bożena Wasyl, Dariusz Milanowski, Janusz |
author_sort | Grenda, Anna |
collection | PubMed |
description | The significance of Akkermansia bacteria presence in gut micobiome, mainly Akkermansia mucinifila, is currently being investigated in the context of supporting therapy and marker for response to immunotherapy in cancer patients. It is indicated that patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) respond better to treatment if this bacterium is present in the intestine. We performed next-generation sequencing of the gut microbiome from patients treated in the first or second line therapy with anti-PD-1 (anti-programmed death 1) or anti-PD-L1 (anti-programmed death ligand 1) monoclonal antibodies. In our study group of 47 NSCLC patients, the percentage of Akkermansiaceae was higher in patients with disease stabilization and with partial response to immunotherapy compared to patients with disease progression. Moreover, we found that a higher percentage of Akkermansiaceae was present in patients with squamous cell carcinoma compared to adenocarcinoma. Our study showed that Akkermansiaceae could be supporting marker for response to immunotherapies in NSCLC patients, nonetheless further in-depth studies should be conducted in the role of Akkermansiaceae in cancer immunotherapy. |
format | Online Article Text |
id | pubmed-9259768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-92597682022-07-08 Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer Grenda, Anna Iwan, Ewelina Chmielewska, Izabela Krawczyk, Paweł Giza, Aleksandra Bomba, Arkadiusz Frąk, Małgorzata Rolska, Anna Szczyrek, Michał Kieszko, Robert Kucharczyk, Tomasz Jarosz, Bożena Wasyl, Dariusz Milanowski, Janusz AMB Express Original Article The significance of Akkermansia bacteria presence in gut micobiome, mainly Akkermansia mucinifila, is currently being investigated in the context of supporting therapy and marker for response to immunotherapy in cancer patients. It is indicated that patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) respond better to treatment if this bacterium is present in the intestine. We performed next-generation sequencing of the gut microbiome from patients treated in the first or second line therapy with anti-PD-1 (anti-programmed death 1) or anti-PD-L1 (anti-programmed death ligand 1) monoclonal antibodies. In our study group of 47 NSCLC patients, the percentage of Akkermansiaceae was higher in patients with disease stabilization and with partial response to immunotherapy compared to patients with disease progression. Moreover, we found that a higher percentage of Akkermansiaceae was present in patients with squamous cell carcinoma compared to adenocarcinoma. Our study showed that Akkermansiaceae could be supporting marker for response to immunotherapies in NSCLC patients, nonetheless further in-depth studies should be conducted in the role of Akkermansiaceae in cancer immunotherapy. Springer Berlin Heidelberg 2022-07-06 /pmc/articles/PMC9259768/ /pubmed/35792976 http://dx.doi.org/10.1186/s13568-022-01428-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Grenda, Anna Iwan, Ewelina Chmielewska, Izabela Krawczyk, Paweł Giza, Aleksandra Bomba, Arkadiusz Frąk, Małgorzata Rolska, Anna Szczyrek, Michał Kieszko, Robert Kucharczyk, Tomasz Jarosz, Bożena Wasyl, Dariusz Milanowski, Janusz Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer |
title | Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer |
title_full | Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer |
title_fullStr | Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer |
title_full_unstemmed | Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer |
title_short | Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer |
title_sort | presence of akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259768/ https://www.ncbi.nlm.nih.gov/pubmed/35792976 http://dx.doi.org/10.1186/s13568-022-01428-4 |
work_keys_str_mv | AT grendaanna presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT iwanewelina presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT chmielewskaizabela presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT krawczykpaweł presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT gizaaleksandra presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT bombaarkadiusz presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT frakmałgorzata presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT rolskaanna presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT szczyrekmichał presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT kieszkorobert presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT kucharczyktomasz presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT jaroszbozena presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT wasyldariusz presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer AT milanowskijanusz presenceofakkermansiaceaeingutmicrobiomeandimmunotherapyeffectivenessinpatientswithadvancednonsmallcelllungcancer |